ACCEPTED ABSTRACTS
ORAL COMMUNICATION
Transplacental delivery of maternal FVIII for induction of FVIII-specific immune tolerance
N-glycan shielded rhADAMTS13 for treatment of immune Thrombotic Thrombocytopenic Purpura
Anti-cysteine/spacer autoantibodies that open the conformation of ADAMTS13 are a common feature of the autoimmune response in immune-mediated thrombotic thrombocytopenic purpura
From coagulation to angiogenesis: possible role of FVIII in endothelial functionality
Syntaxin 5 is Essential for Golgi Integrity, Weibel-Palade Body Biogenesis and Stimulus-Induced Von Willebrand Factor Secretion from Endothelial Cells
Developing a model for studying Von Willebrand disease with hiPSC-derived endothelial cells
ELECTRONIC POSTER
Liver Gene Therapy with Lentiviral Vectors Corrects Hemophilia A in Mice and Achieves Normal-Range Factor VIII Activity in Non-Human Primates
Genetic determination of enhanced von Willebrand factor clearance
PAD4-mediated citrullination of ADAMTS13 in sepsis and immune-mediated TTP
Preclinical efficacy and safety assessment of a recombinant factor IX variant that functions independently of factor VIII in combination with current hemophilia A therapeutics
Differential release of VWF and VWF-propeptide from platelet alpha-granules
The specificity of the assay determines the measurement of FVIII antigen levels in patients with severe haemophilia A
Selection of immuno-dominant T cell epitopes from the repertoire of FVIII derived peptides presented on MHC class II
The IgG-degrading enzyme from Streptococcus pyogenes as a new tool for the elimination of factor VIII inhibitors
IgG2 as hallmark of inhibitor persistence in PUPs: a longitudinal analysis along exposure to FVIII
Interaction of factor XI with ligands studied with novel anti-factor XI nanobodies
The safety and efficacy of N8-GP in previously untreated patients (PUPs) with severe haemophilia A: Interim results from the main and extension phases of pathfinder6
Genetic characterization of von Willebrand disease type 2 in Milan Cohort patients
Evaluation of the different platelet-dependent von Willebrand factor activity assays capacity to assess the in vivo inhibitory effect of caplacizumab on the VWF-platelet interaction
A post-hoc analysis of temporarily decreased incremental recovery (IR) observed in a subset of previously untreated patients (PUPs) with haemophilia A treated with N8-GP
Inhibitor development upon switch from plasma-derived to recombinant FVIII in PUPs with severe haemophilia A: preliminary analysis of the PUP-SWITCH study
Functional transitory anti emicizumab antibody creating bleeding episodes
Identification of small interfering RNAs for allele-selective silencing of murine von Willebrand factor
Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in hemophilia A?
GEPHARD – the PUP cohort of the 'Standing Commission Paediatrics of the Society for Thrombosis and Haemostasis Research' - a progress report
The Extracellular Protease EpiP from S. aureus Triggers Blood Coagulation by Proteolytically Activating Prothrombin and Platelet Protease-Activated Receptor 1
Catridecacog in the treatment of an Italian population of patients with FXIII deficiency: from pharmacokinetics to clinical outcomes (The Italian rFXIII study)
Measurement of von Willebrand factor levels via fiber optic-surface plasmon resonance
Exploring the role of Factor VIII as a potential player in cancer cells
D-dimer as a predictive marker for mortality in hospitalized COVID-19 patients
A combination of complement-related variants predicts severe COVID-19 with high sensitivity and specificity
Evaluation of Health-related quality of life in patients with von Willebrand disease on long-term prophylaxis: WiSH-QoL intermediary results
Investigation of ADAMTS13-independent cleavage and regulation of von Willebrand Factor
Real-world experience with emicizumab in an italian paediatric cohort: focus on PUPs and tolerized children
Might Loss-of-Function FII-Variant-543R>L—a Major-Determinant of Mexican-American Coagulability—Contribute to the High-Risk of FVIII-Inhibitors in Hemophilia-Patients of this Ethnicity?
Safety of FEIBA and emicizumab (SAFE): Dose Escalation Study Evaluating the Safety of in vivo Administration of activated Prothrombin Complex Concentrate in Hemophilia A Patients on Emicizumab
Deep molecular mechanisms of F8 exon 19 variants and translational approaches in Hemophilia A
Time from the inhibitor detection to the start of immune tolerance induction and the outcome of immune tolerance induction: results from the Brazilian Immune Tolerance (BrazIT) Study
Development of a new ELISA method for anti-FVIIa antibody measurement
Transplacental delivery of recombinant Fc-fused factor VIII (rFVIIIFc) in FVIII-deficient mice
Prothrombotic alterations of von Willebrand factor level and ADAMTS13 activity in hospitalized COVID-19 patients
Cost-effectiveness analysis of the Brazilian Immune Tolerance Induction Protocol with prophylaxis with bypassing agents or emicizumab
FACTOR V DEFICIENCY AND DEEP VENOUS THROMBOSIS: A CASE REPORT
Elevated soluble C5b-9 as a rough marker of complement activation in complications of sickle cell disease
A patient with FVIII inhibitors on emicizumab prophylaxis switching to immune tolerance induction – laboratory issues
Emicizumab for the Management of Children with Severe Hemophilia A: Experience from Hemophilia Centres in Lithuania
Confirmed safety profile of BAY 94-9027 prophylaxis for ≥5 Years: outcomes from the PROTECT VIII and PROTECT VIII Kids extension studies
PUBLICATION ONLY
Automatic segmentation of arteries, arterioles and glomeruli on kidney biopsies with thrombotic microangiopathies
ACQUIRED HAEMOPHILIA: CLINICAL MANIFESTATIONS AND MANAGEMENT EXPERIENCE FROM A SINGLE CENTRE
Alteration of the intrinsic proliferation capability of haemophilic CD8 T cells
OFF LABEL USE OF MULTIPLE AGENTS IN ORDER TO CONTROL BLEEDING EPISODES IN A BOY WITH WISKOTT-ALDRICH SYNDROME
Coagulation Disorders in Paediatric Patients Hospitalized due to SARS-CoV-2 Infection
HEAVY MENSTRUAL BLEEDING IN VON WILLEBRAND PATIENTS – THE REALITY OF A TERTIARY CARE HOSPITAL
Coagulation profile and laboratory data in Covid 19 patients on chronic anticoagulation or antiplatelet therapy
RECURRENT INTRAVITREAL ANTI-VEGF TREATMENT IN HEMOPHILIA B PATIENT WITH OCULAR DEGENERATION
MANAGEMENT OF MAJOR SURGERY IN A PATIENT WITH TYPE 3 VON WILLEBRAND DISEASE WHO HAS LOW TITER INHIBITOR
Words in hemophilia: a project for a better patient engagement
How can we better understand complications arising from FVIII substitute therapies?
VON WILLEBRAND DISEASE TYPE 2B AND DDAVP. STILL A TREATMENT DRUG TO AVOID?
Thrombosis in inherited hypofibrinogenemia: a case report
A case of VITT (vaccine-induced immune thrombotic thrombocytopenia) without cerebral vein thrombosis post Vaxzevria vaccine exposure: clinical and laboratory diagnosis and favourable outcome
EMICIZUMAB PROPHYLAXIS IN ADULT PATIENTS WITH SEVERE HAEMOPHLIA A INHIBITORS : EXPERIENCE FROM A GREEK HAEMOPHILIA CENTRE
CLINICAL EFFICACY AND SAFETY OF PLASMA-DERIVED VON WILLEBRAND FACTOR- FVIII COMPLEX CONCENTRATES, IN PATIENTS WITH VON WILLEBRAND DISEASE IN ITALY: STUDY DESIGN
THE STUDY OF THE EFFECT OF SUBSTANCES ARE USED IN THE PROCESS OF PURIRFICATION ON THE DETERMINATION OF FACTOR VIII ACTIVITY
THE CHALLENGING MANAGEMENT OF PREGNANCY IN TYPE 3 VON WILLEBRAND DISEASE: LABOR, DELIVERY AND POSTPARTUM. A CASE REPORT
Massive haemothorax in hemophilia A patient with high factor VIII inhibitors treated successfully with high dose of factor VIII
Application of the ISTH-BAT In Congenital Fibrinogen Disorders
PRIOR PLASMA FRACTIONATION: СHOICE OF THE METHOD PRECIPITATION AND SEARCH FOR RAW MATERIALS
IMMUNE THROMBOCYTOPENIAPURPURA (ITP) RELAPSE OR VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA (VITT).WHAT CAN WE CONCLUDE FROM A CASE REPORT?